Macular Degeneration St. George Utah


Arsanis Inc. (NASDAQ:ASNS) and Coherus BioSciences Inc. (NASDAQ:CHRS), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arsanis Inc. N/A 0.00 44.86M -3.14 0.00
Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00

In table 1 we can see Arsanis Inc. and Coherus BioSciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Arsanis Inc. 0.00% -103.8% -70.8%
Coherus BioSciences Inc. 0.00% -741.7% -126.2%

Liquidity

The Current Ratio and a Quick Ratio of Arsanis Inc. are 5.1 and 5.1. Competitively, Coherus BioSciences Inc. has 5.3 and 5.3 for Current and Quick Ratio. Coherus BioSciences Inc.’s better ability to pay short and long-term obligations than Arsanis Inc..

Analyst Ratings

In next table is pshown Arsanis Inc. and Coherus BioSciences Inc.’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arsanis Inc. 0 0 0 0.00
Coherus BioSciences Inc. 0 0 1 3.00

Competitively Coherus BioSciences Inc. has a average target price of $28, with potential upside of 139.32%.

Insider and Institutional Ownership

Arsanis Inc. and Coherus BioSciences Inc. has shares owned by institutional investors as follows: 75.5% and 95.7%. Arsanis Inc.’s share owned by insiders are 1.8%. Competitively, Coherus BioSciences Inc. has 0.1% of it’s share owned by insiders.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. The company’s preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.




Source link



WAIKOLOA, Hawaii ― Elias Reichel, MD, discusses the latest advances in gene therapy for inherited retinal diseases, age related macular …



Source link


Doctors aren’t sure what causes age-related macular degeneration, a disease that affects millions of people in the United States.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

Also called AMD, it is known for causing blurred central vision due to damage to the macula a small area at the back of the eye. Currently, there is no cure.

But there are known risk factors that eye care professionals often use to help determine a patient’s likelihood of developing AMD.

A key factor: age. The disease is most likely to occur after age 60, according to the National Eye Institute.

“People who have had more birthdays are the ones who are susceptible,” says Julie Rosenthal, M.D., a Kellogg Eye Center retina specialist. It’s also more common in women and whites.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

That’s why at-risk patients should get regular eye exams that include pupil dilation and further macular degeneration tests, such as an optical coherence tomography (OCT) test. 

Other strategies, however, can help slow or possibly prevent severe AMD, notes Rosenthal. She shared healthy habits that can benefit everyone’s eye health as they grow older:

Ways to prevent age-related macular degeneration:

1. Quit smoking

“Rules 1, 2 and 3 are stop smoking,” says Rosenthal. Smoking may double a person’s risk of developing AMD. And the habit exposes you to dangerous free radicals, unstable molecules that can cause cellular damage and keep nutrients from reaching the retina. The sooner you can quit, the better.

2. Know your family history

People with a first-degree relative affected by AMD have a much greater risk of developing it, too. Those with family ties to the disease should be vigilant for potential symptoms that include difficulty recognizing faces, struggling to adapt to low light and seeing straight lines that appear wavy.

SEE ALSO: Impaired Vision? Create a Fall Prevention Plan with These Tips

3. Eat leafy greens

Load up your plate with spinach, kale and Swiss chard, among other green veggies. “They have a lot of antioxidant vitamins,” Rosenthal says. Those nutrients help protect against cellular damage from free radicals, which can contribute to eye disease.

4. Take supplements

Patients with deficient diets might consider multivitamins. And people at risk of advanced AMD should ask their doctor about a specialized blend of supplements known as AREDS. The macular degeneration vitamins are “not a treatment or cure but can decrease your risk of getting the more severe forms of AMD,” Rosenthal says.

5. Wear sunglasses

Such eyewear offers protection from UV and blue light that can cause retinal damage from repeat exposure (the American Macular Degeneration Foundation recommends wearing a pair with a “UV 400” label). “Lifetime use is probably helpful,” Rosenthal says.

SEE ALSO: Watch Out for These 5 Summer Eye Dangers

6. Maintain a healthy blood pressure and weight

Poor blood circulation due to hypertension can also restrict blood flow to the eyes, thus contributing to AMD. Losing weight is a proven way to lower blood pressure; even small gains help especially if you already have hypertension.

7. Test yourself with an Amsler grid

The tool that helps doctors detect vision problems related to macular damage can be used at home. If, after staring at the paper grid, you notice that the central part of your vision in one eye has become darker or the grid lines are wavy, call your doctor. Keep your Amsler grid in a place that reminds you to check it daily.



Source link


As Biotechnology companies, Kodiak Sciences Inc. (NASDAQ:KOD) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kodiak Sciences Inc. N/A 0.00 38.35M -1.07 0.00
ZIOPHARM Oncology Inc. 1.74M 172.57 75.56M -0.54 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Kodiak Sciences Inc. and ZIOPHARM Oncology Inc..

Profitability

Table 2 has Kodiak Sciences Inc. and ZIOPHARM Oncology Inc.’s net margins, return on equity and return on assets (ROA).

Net Margins Return on Equity Return on Assets
Kodiak Sciences Inc. 0.00% 0% 0%
ZIOPHARM Oncology Inc. -4,342.53% 58.6% -89.9%

Liquidity

The Current Ratio and a Quick Ratio of Kodiak Sciences Inc. are 2.3 and 2.3. Competitively, ZIOPHARM Oncology Inc. has 0.8 and 0.8 for Current and Quick Ratio. Kodiak Sciences Inc.’s better ability to pay short and long-term obligations than ZIOPHARM Oncology Inc..

Analyst Ratings

In next table is given Kodiak Sciences Inc. and ZIOPHARM Oncology Inc.’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kodiak Sciences Inc. 0 0 0 0.00
ZIOPHARM Oncology Inc. 0 0 1 3.00

Competitively ZIOPHARM Oncology Inc. has a average price target of $5, with potential upside of 134.74%.

Insider and Institutional Ownership

Kodiak Sciences Inc. and ZIOPHARM Oncology Inc. has shares held by institutional investors as follows: 13.6% and 41.4%. Kodiak Sciences Inc.’s share held by insiders are 11.6%. Comparatively, ZIOPHARM Oncology Inc. has 1.77% of it’s share held by insiders.

Summary

On 5 of the 9 factors ZIOPHARM Oncology Inc. beats Kodiak Sciences Inc..

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.




Source link


A West Virginia reverend said the miracle he waited 14 years for has restored his vision, enabling him to relive his daughter’s wedding through photos and videos and see the faces of his four grandchildren for the first time.

Rev. Philip Dunn, of the Valley Christian Assembly in Charleston, never left the pulpit after losing his sight to cataracts and macular degeneration and listened to the Bible on tape to prepare his services.

BANGLADESHI ‘TREE MAN’ REPORTEDLY BACK IN HOSPITAL WITH  MORE GROWTHS

“I knew in my heart I was going to be able to see again, I just didn’t know when,” Dunn, now 61, told WCHS.

According to the Centers for Disease Control and Prevention (CDC), cataract, which is the clouding of the eye’s lens, is a leading cause of blindness worldwide, and the leading cause of vision loss in the U.S. The condition can occur at any age, for a variety of reasons, with an estimated 20.5 million Americans aged 40 and older having cataract in one or both eyes. Dunn said he was told that the diagnosis wouldn’t bother him for a few years, but within months he was seeing black dots.

“That was the beginning of macular degeneration,” he told WCHS.

The secondary condition, also referred to as age-related macular degeneration (AMD), is associated with aging and damages sharp and central vision. According to the CDC, central vision is needed for seeing objects clearly, and for common everyday tasks. The agency estimates that the condition affects 1.8 million Americans over age 40, and said it is the leading cause of permanent impairment of reading and fine or close-up vision among people 65 and older.

HAWAII TODDLER WITH ECZEMA SUFFERS SEVERE ‘LOBSTER’ RED, OOZING SKIN REACTION TO STEROID CREAM

“Even as my vision got worse and things got more difficult, I just, every day I woke up, I woke up with an expectation that maybe today I would get my miracle,” Dunn told WCHS.

The miracle came for Dunn in August, when he began experiencing a severe headache in his left eye. Doctors reportedly determined the pain to be a ruptured cataract. He underwent surgery to remove it, and when he removed the patch, he realized his sight had been restored.

“I went into the kitchen, my wife said, ‘Honey, you took the patch off,’ I said ‘Yeah,’ she said, ‘what do you see?’ I said, ‘I can see you!’” he told WCHS. “She was the first face I saw in 14 years.”

A second surgery reportedly stored sight in his right eye as well.

CLICK HERE TO GET THE FOX NEWS APP

Dunn said his vision loss and restoration has caused him to urge others to “celebrate every moment,” and “maximize each day.” He isn’t sure if his vision is permanent, so shortly after being able to see again he took a road trip to California in the minivan he hasn’t driven since losing his sight.

“For the last 14 years I’ve dreamed of doing it, and I didn’t realize when that was going to come and it was finally a reality,” he told WCHS.



Source link


Increased eye diseases, technological advances in ophthalmic devices, government efforts to raise awareness of visual impairment control, and increased disposable income due to increased spending by individuals are major drivers of the expansion of the eye exam equipment market.

The market for vision testing equipment is categorized by type and by end user. OCT, fundus camera, ophthalmology, ultrasound, autorefractor, slit lamp, corneal topography, lens meter, chart projector, and wavefront analyzer. Retina and glaucoma screening products in this area accounted for the largest portion of the worldwide market for ophthalmic test equipment. This may be due to increased retinal diseases and glaucoma, technological advances in ophthalmic screening equipment, increased diversity in ophthalmic clinics, and increased access to modern and sophisticated ophthalmic diagnostic equipment.

Get for sample copy of this report here:
www.theresearchinsights.com/request_sample.php?id=6646

Based on this application, the global eye exam equipment market is divided into four categories of general inspection, glaucoma, cataracts and other applications. Other applications include the diagnosis of diabetic retinopathy, age-related macular degeneration, eye swelling, CMV retinitis, color blindness, and other diseases including diabetic macular edema. The incidence of glaucoma is expected to increase further around the world. Although the symptoms of glaucoma are more pronounced than cataracts, the highest CAGR was recorded in the global market throughout the forecast period as the awareness of effective diagnosis and treatment of cataracts increased.

Leading market players and manufacturers are studied to help give a brief idea about them in the report. The challenges faced by them and the reasons they are on that position is explained to help make a well-informed decision. Competitive landscape of Eye Exam Equipment market is given presenting detailed insights into the company profiles, developments, merges, acquisitions, economic status and best SWOT analysis.

Included key players are:

Carl Zeiss, Haag-Streit, Topcon, NIDEK, Heidelberg Engineering, Escalon, Novartis, Valent, Canon, Essilor, Heine Optotechnik, Luneau Technology etc.

Get for discount copy of this report here:
www.theresearchinsights.com/ask_for_discount.php?id=6646

The growth of the industrial sector is one of the main driving factors that is responsible for the growth and development of the Eye Exam Equipment market worldwide. The modern Internet of Things is following the surge of digitalization of innovation that builds up a scaffold amongst the physical and advanced world. The model follows the growth status of the physical product growth cycle and enables the client to check the performance and outcome of the process. Dealing with all the outline records for the market among suppliers and distributors is one of the significant restrictions confronted by the market.

In the last section of the report, the prime manufacturers operating in the global Eye Exam Equipment market have been presented. These manufacturers have been analyzed in terms of key attributes such as gross, cost, gross margin, revenue, product specifications, product picture, company profile, and contact information.

About us

The Research Insights – A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

The Research Insights
Robin
(Sales Manager)
+91-996-067-0000
sales@theresearchinsights.com
www.theresearchinsights.com/

This release was published on openPR.



Source link


This finding was the first genotype-functional phenotype association found in AMD research.

AMDjoomlaLayers of the retina are shown by optical coherence tomography, as are drusen (bumps), the characteristic lesions of age-related macular degeneration (AMD)Researchers from the University of Alabama at Birmingham Department of Ophthalmology and Visual Sciences, along with collaborators from the University of Iowa, have discovered a genetic biomarker that is associated with age-related macular degeneration and delayed rod-mediated dark adaptation — the first visual function for incident AMD in older adults with normal macular health and early AMD.

According to the Centers for Disease Control and Prevention, AMD is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans age 65 years and older. 

Professors Cynthia Owsley, Ph.D., and Christine A. Curcio, Ph.D., say there are no current proven strategies for preventing AMD or stopping its progression early in the disease when sight could be saved. Two of the strongest genetic associations for age-related macular degeneration are common polymorphisms — variants in DNA sequence — at chromosome 1 (CFH) and chromosome 10 (ARMS2).

“We have previously shown that delayed rod-mediated dark adaptation is the first functional risk factor for early AMD,” said Owsley, the Nathan E. Miles Chair of Ophthalmology. “Delayed dark adaptation means it takes these individuals much longer to adapt to a dark environment — for example, after entering a darkened movie theater — than other individuals. This was important, because vision in bright light was known to be relatively preserved late into the disease. Night vision is affected much earlier. ”

In other words, older adults with delayed dark adaptation have a heightened risk for developing AMD within the next few years.

In the recently published study, Owsley and Curcio, with collaborators Robert F. Mullins and Edwin M. Stone of the University of Iowa, established that older adults with delayed dark adaptation are also more likely to have these high-risk genetic polymorphisms at chromosome 1 and chromosome 10.

“This finding was the first genotype-functional phenotype association found in AMD research,” Owsley said. “What we find particularly exciting is that the ARMS2 genotype-phenotype association emerges even at pre-clinical stages of AMD — that is, in older adults who do not yet have AMD. Being able to assess risk at such an early stage could lead to new preventive measures.”

Owsley says the ARMS2 gene is poorly understood from a biological standpoint and is also challenging to study because it is not expressed in adults.

“However, our study suggests that making ARMS2 a research priority will lead to new ways of tackling AMD and developing treatments to prevent this disabling disease,” she said.

Funding for this research was provided by National Institutes of Health grants, the Dorsett Davis Discovery Fund, the National Center for Advanced Translational Sciences of NIH, the Alfreda J. Schueler Trust, the EyeSight Foundation of Alabama, Research to Prevent Blindness and the Macula Foundation.





Source link


Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Bbva Compass Bancshares Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 7.38% based on its latest 2018Q3 regulatory filing with the SEC. Bbva Compass Bancshares Inc bought 1,078 shares as the company’s stock declined 4.42% with the market. The institutional investor held 15,687 shares of the health care company at the end of 2018Q3, valued at $6.34 million, up from 14,609 at the end of the previous reported quarter. Bbva Compass Bancshares Inc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $43.07 billion market cap company. The stock decreased 1.59% or $6.43 during the last trading session, reaching $398.32. About 583,523 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 1.07% since January 23, 2018 and is uptrending. It has outperformed by 1.07% the S&P500. Some Historical REGN News: 16/05/2018 – POSITIVE PHASE 3 TRIAL OF DUPIXENT® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS; 11/05/2018 – Bayer: Eylea Treats Visual Impairment From Macular Degeneration; 01/05/2018 – REGENERON: EXPRESS SCRIPTS SELECTS PRALUENT EXCLUSIVE THERAPY; 28/03/2018 – Regeneron CEO ‘optimistic’ will strike deals to lower $14,000 per-year cholesterol drug; 10/03/2018 – Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?; 19/03/2018 – NOVARTIS NOVN.S FILES PATENT INFRINGEMENT LAWSUIT AGAINST REGENERON REGN.O OVER LATTER’S MANUFACTURING OF EYLEA, ZALTRAP — COURT FILING; 10/03/2018 – Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam; 23/04/2018 – Regeneron at J.P. Morgan Spring Biotech Conference May 8; 21/03/2018 – $REGN $ALNY NASH collaboration; 18/05/2018 – Regeneron Announces Upcoming Investor Conference Presentation

Jrm Investment Counsel Llc increased its stake in Blackstone Mtg Tr Inc (BXMT) by 11.74% based on its latest 2018Q3 regulatory filing with the SEC. Jrm Investment Counsel Llc bought 46,612 shares as the company’s stock rose 1.60% while stock markets declined. The institutional investor held 443,606 shares of the consumer services company at the end of 2018Q3, valued at $14.87M, up from 396,994 at the end of the previous reported quarter. Jrm Investment Counsel Llc who had been investing in Blackstone Mtg Tr Inc for a number of months, seems to be bullish on the $3.96 billion market cap company. The stock decreased 0.09% or $0.03 during the last trading session, reaching $33.12. About 232,739 shares traded. Blackstone Mortgage Trust, Inc. (NYSE:BXMT) has risen 7.18% since January 23, 2018 and is uptrending. It has outperformed by 7.18% the S&P500. Some Historical BXMT News: 24/04/2018 – Blackstone Mortgage Trust 1Q EPS 56c; 10/04/2018 – FINANCING FOR ‘THE SPIRAL’ PROJECT INCLUDES $1.9 BLN IN EQUITY FROM TISHMAN AND OTHERS; $1.8 BLN CONSTRUCTION LOAN FROM BLACKSTONE MORTGAGE TRUST INC BXMT.N; 22/03/2018 BLACKSTONE MORTGAGE TRUST REPORTS OFFERING OF $220M NOTES; 22/03/2018 – BLACKSTONE MORTGAGE TRUST INC – TO USE PROCEEDS FROM OFFERING TO ORIGINATE AND PURCHASE ADDITIONAL COMMERCIAL MORTGAGE LOANS; 10/04/2018 – Blackstone Mortgage Trust Announces Closing of $1.8 B Financing for Tishman Speyer’s Spiral Development Project; 21/04/2018 – DJ Blackstone Mortgage Trust Inc Cla, Inst Holders, 1Q 2018 (BXMT); 24/04/2018 – BLACKSTONE MORTGAGE TRUST INC QTRLY CORE SHR $0.64; 10/04/2018 – TISHMAN SPEYER SECURES ALL FINANCING TO BUILD $3.7 BLN 65-STORY OFFICE TOWER IN NEW YORK’S HUDSON YARDS; 24/04/2018 – BLACKSTONE MORTGAGE 1Q CORE EPS 64C, EST. 63C; 24/04/2018 – Blackstone Mortgage Trust 1Q Net $61M

Investors sentiment decreased to 1.14 in 2018 Q3. Its down 0.05, from 1.19 in 2018Q2. It turned negative, as 39 investors sold REGN shares while 173 reduced holdings. 89 funds opened positions while 153 raised stakes. 70.41 million shares or 0.23% more from 70.25 million shares in 2018Q2 were reported. Brinker Capital owns 13,550 shares or 0.2% of their US portfolio. 90 are owned by Hudock Capital Grp Ltd Liability Co. Meiji Yasuda Life Co holds 3,143 shares. Capital Int Invsts has invested 0.32% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Cetera Advsrs Ltd Llc has 0.02% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 952 shares. Private Advisor Grp Limited Liability holds 0.03% or 3,683 shares. The Pennsylvania-based Janney Montgomery Scott Ltd Company has invested 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Assetmark Inc stated it has 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Public Employees Retirement Association Of Colorado invested in 0.03% or 14,225 shares. Tobam holds 47,719 shares. Andra Ap accumulated 0.13% or 12,900 shares. Nomura Asset Mgmt Limited has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Harding Loevner Limited Partnership holds 1.34% or 636,898 shares. High Pointe Cap Mngmt Ltd Com invested in 1.71% or 3,140 shares. First Republic Inv Management Incorporated holds 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 8,648 shares.

Bbva Compass Bancshares Inc, which manages about $1.69B US Long portfolio, decreased its stake in Alibaba Group Hldg Ltd (NYSE:BABA) by 3,163 shares to 95,127 shares, valued at $15.67M in 2018Q3, according to the filing. It also reduced its holding in Molson Coors Brewing Co (NYSE:TAP) by 11,051 shares in the quarter, leaving it with 28,544 shares, and cut its stake in Ishares Cohen & Steers Reit Et (ICF).

Among 34 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 20 Hold. Therefore 38% are positive. Regeneron Pharmaceuticals Inc. had 139 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Robert W. Baird to “Underperform” on Tuesday, August 1. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Sell” rating given on Wednesday, August 5 by UBS. On Thursday, September 7 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Piper Jaffray on Sunday, February 11. On Monday, August 31 the stock rating was maintained by RBC Capital Markets with “Buy”. Argus Research maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, July 16 with “Buy” rating. The firm has “Sell” rating by Chardan Capital Markets given on Monday, November 7. The firm has “Neutral” rating given on Friday, February 9 by BTIG Research. Barclays Capital maintained it with “Equal Weight” rating and $595.0 target in Wednesday, August 5 report. The rating was maintained by BMO Capital Markets on Tuesday, July 18 with “Hold”.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Seekingalpha.com which released: “Regeneron: Regenerating As Usual – Seeking Alpha” on November 30, 2018, also Nasdaq.com with their article: “Regeneron (REGN) to Report Q2 Earnings: What’s in the Cards? – Nasdaq” published on July 30, 2018, Investorplace.com published: “Value Investors Should Buy into the Teva Stock Dip – Investorplace.com” on December 26, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Nasdaq.com and their article: “Noteworthy Wednesday Option Activity: REGN, RMD, DISH – Nasdaq” published on October 24, 2018 as well as Nasdaq.com‘s news article titled: “Why Is Regeneron (REGN) Up 2.4% Since Last Earnings Report? – Nasdaq” with publication date: December 06, 2018.

Since August 22, 2018, it had 0 insider buys, and 8 sales for $47.14 million activity. $2,294 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by VAGELOS P ROY on Wednesday, December 12. BROWN MICHAEL S sold $784,524 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, September 27. Fenimore Christopher R. also sold $663,381 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Another trade for 104,552 shares valued at $42.52M was sold by Sanofi.

Investors sentiment increased to 1.61 in Q3 2018. Its up 0.26, from 1.35 in 2018Q2. It increased, as 15 investors sold BXMT shares while 61 reduced holdings. 41 funds opened positions while 81 raised stakes. 74.74 million shares or 7.02% more from 69.84 million shares in 2018Q2 were reported. Raymond James Ser Advsr Inc reported 27,249 shares or 0% of all its holdings. Janney Capital Mgmt Ltd Llc owns 12,153 shares. Round Table Svcs Ltd Liability Corp holds 0.11% of its portfolio in Blackstone Mortgage Trust, Inc. (NYSE:BXMT) for 9,500 shares. Amalgamated Natl Bank owns 15,105 shares. Jpmorgan Chase holds 0% or 189,778 shares. Aqr Capital Lc accumulated 0% or 76,725 shares. United Cap Advisers Limited Liability has invested 0.04% in Blackstone Mortgage Trust, Inc. (NYSE:BXMT). Price T Rowe Md holds 0% or 44,614 shares in its portfolio. Delphi Mgmt Inc Ma accumulated 66,130 shares or 1.42% of the stock. Great West Life Assurance Co Can holds 0% or 10,001 shares. Clough Cap Prns Limited Partnership reported 957,700 shares or 3.03% of all its holdings. Botty Ltd Llc owns 329,341 shares. Bartlett & Limited Co accumulated 2,570 shares. Credit Suisse Ag invested 0% of its portfolio in Blackstone Mortgage Trust, Inc. (NYSE:BXMT). Next Grp accumulated 1,000 shares.

Among 11 analysts covering Blackstone Mortgage Trust Inc (NYSE:BXMT), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Blackstone Mortgage Trust Inc had 23 analyst reports since January 26, 2016 according to SRatingsIntel. Wood maintained the stock with “Outperform” rating in Friday, April 7 report. The stock has “Neutral” rating by Bank of America on Thursday, December 15. On Monday, January 9 the stock rating was downgraded by Wells Fargo to “Market Perform”. Keefe Bruyette & Woods maintained Blackstone Mortgage Trust, Inc. (NYSE:BXMT) on Thursday, July 6 with “Buy” rating. Deutsche Bank downgraded Blackstone Mortgage Trust, Inc. (NYSE:BXMT) rating on Monday, December 17. Deutsche Bank has “Hold” rating and $35 target. The stock of Blackstone Mortgage Trust, Inc. (NYSE:BXMT) has “Buy” rating given on Friday, December 1 by FBR Capital. FBR Capital maintained it with “Buy” rating and $33.0 target in Thursday, February 15 report. The rating was downgraded by J.P. Morgan to “Hold” on Tuesday, February 6. Keefe Bruyette & Woods maintained the shares of BXMT in report on Tuesday, August 8 with “Buy” rating. JMP Securities downgraded the stock to “Mkt Perform” rating in Thursday, February 16 report.

Jrm Investment Counsel Llc, which manages about $274.83 million and $149.75 million US Long portfolio, decreased its stake in Williams Cos Inc Del (NYSE:WMB) by 54,197 shares to 34,550 shares, valued at $939,000 in 2018Q3, according to the filing.

More notable recent Blackstone Mortgage Trust, Inc. (NYSE:BXMT) news were published by: Seekingalpha.com which released: “This 7.9%-Yielding Real Estate Finance Company Is A Strong Buy – Seeking Alpha” on February 25, 2018, also Seekingalpha.com with their article: “Blackstone Mortgage Trust: Buy The More Defensive Of The Large CRE mREITs – Seeking Alpha” published on October 31, 2018, Seekingalpha.com published: “Commercial Mortgage REITs: Watch Them Like A Hawk – Seeking Alpha” on July 10, 2018. More interesting news about Blackstone Mortgage Trust, Inc. (NYSE:BXMT) were released by: Finance.Yahoo.com and their article: “Blackstone Mortgage Trust Inc (NYSE:BXMT): Ex-Dividend Is In 2 Days, Should You Buy? – Yahoo Finance” published on June 25, 2018 as well as Seekingalpha.com‘s news article titled: “Blackstone Mortgage Trust, Inc. (BXMT) CEO Stephen Plavin on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: July 25, 2018.

Since August 31, 2018, it had 1 insider purchase, and 12 insider sales for $188,099 activity. 806 shares were sold by Armer Douglas N., worth $28,154 on Friday, November 30. The insider Marone Anthony F. JR sold 247 shares worth $8,605. Shares for $101,610 were bought by Cotton Leonard W.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart




Source link


He went blind 14 years ago, but now he can see again.

The Rev. Phillip Dunn was diagnosed with cataracts in 2003, when he was 45 years old. At the time, the doctor told him not to worry about because it “probably won’t give you trouble for years,” he recounted to WCHS-TV.

The optometrist was wrong. Just a few months later, Dunn said, he started seeing black dots in the center of his vision — a symptom he later learned was the beginning stages of macular degeneration, a condition for which there is no known cure.

Dunn’s vision problems soon turned to complete blindness.

“For the next 14 years, you know, my vision just dropped out,” he said.

How did he react to blindness?

Rather than allowing the devastating developments get him down, the southern preacher continued to deliver sermons at his church, Valley Christian Assembly, only now he was using an audio version of the Bible instead of reading Scripture to prepare for his messages.

Christian Woman Awarded $21.5 Million After Employer Fired Her for Refusing to Work Sundays

A series of good things happened to Dunn and his family while he was unable to see. He and his wife walked their daughter down the aisle to get married and now they have four grandchildren.

His life was good. Then things started changing once again.

How did his vision return?

Dunn said he “knew in my heart I was going to be able to see again,” though he wasn’t sure when it would happen.

In August, the pastor finally started to see again — a development he believes is nothing short of miraculous. It all started with a severe headache behind his left eye.

After going to the hospital, he learned one of his cataracts had ruptured. Since that could cause irreparable damage to his optic nerve, Dunn was rushed into surgery to have the cataract removed.

When he opened his eye, the doctor was hoping he would see light and shadows. But he ended up seeing much more than that. Standing in his kitchen after the surgery, Dunn saw someone he hasn’t seen in 14 years: his wife.

Small Business Owner’s Defiant Stand Against ‘Tyrannical’ New Abortion Law Is Making Waves

“I went in the kitchen, my wife said, ‘Honey, you took the patch off.’ I said, ‘Yeah.’ She said, ‘What do you see?’ I said, ‘I can see you!’ She was the first face I saw in 14 years,” the pastor recounted.

What has he done since his sight came back?

Shortly after his vision was restored, Dunn was finally able to see the father-daughter wedding dance he and his daughter made up when she was little and he got to see what his four grandchildren look like.

He was also quick to start driving again. Just three weeks after his vision returned, Dunn was behind the wheel of a car, traveling to Florida and then on a road trip to California in his 1998 minivan.

The pastor continues to make the most of his renewed vision, though it remains uncertain how long it will last. For now, he is simply grateful to God for the unexpected gift.





Source link



WAIKOLOA, Hawaii — The number of anti-VEGF injections given to patients with neovascular age-related macular degeneration did not appear to …



Source link